Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021
November 08, 2021 08:00 ET | Neurona Therapeutics
IND cleared by the FDA to enable initiation of Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant focal epilepsy Supporting preclinical data demonstrate seizure-freedom in up to 68%...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients
November 04, 2021 08:00 ET | Neurona Therapeutics
SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders,...
reMYND logo 1.png
reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program
November 04, 2021 07:00 ET | reMYND
Press Release reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program Leuven Belgium, 4 November 2021: reMYND NV, a clinical stage company...
Researchers boost human mental function with brain stimulation
November 01, 2021 09:28 ET | University of Minnesota Medical School
MINNEAPOLIS/ST. PAUL, Nov. 01, 2021 (GLOBE NEWSWIRE) -- In a pilot human study, researchers from the University of Minnesota Medical School and Massachusetts General Hospital show it is possible to...
TIP_link_300x300.jpg
Blood Brain Barrier Technologies Market Size ($5,101.94Mn by 2028) Lead by Neurological Disorders (25.5% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
October 21, 2021 11:42 ET | The Insight Partners
New York, Oct. 21, 2021 (GLOBE NEWSWIRE) -- The new research study on the Blood Brain Barrier Technologies Market Size and Forecast to 2028 By Technology (Bispecific Antibody RMT Approach, Trojan...
researchdrivelogo.jpg
Global Neuromodulation Devices Market to Undergo Significant Growth Due to Rising Adoption for Neuromodulation Devices in COVID-19 Pandemic – Exclusive Report [150 Pages] By Research Dive
August 25, 2021 09:02 ET | Research Dive
New York, USA, Aug. 25, 2021 (GLOBE NEWSWIRE) -- A latest report on the global neuromodulation devices market published by Research Dive sheds light on the impact of COVID-19 pandemic on the current...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 16, 2021 08:00 ET | Praxis Precision Medicines, Inc.
Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD) Enrollment on track for 1H22 topline results in PRAX-114 Phase 2/3 Aria Study for monotherapy...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders
June 22, 2021 08:30 ET | Neurona Therapeutics
Syndicate includes premier healthcare investors steeped in neurology Erica Whittaker, Ph.D., head of UCB Ventures, joins Neurona’s board of directors Latest financing brings total...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)
June 16, 2021 08:00 ET | Neurona Therapeutics
Supporting data in preclinical model of drug-resistant epilepsy demonstrate seizure-freedom in 70% of the NRTX-1001 cell therapy treatment group versus 5% in the control group Data demonstrate...
brsf.png
Brain Scientific Receives Purchase Order and Begins Shipping Its Pediatric NeuroCap™ EEG Headsets
May 24, 2021 08:30 ET | Brain Scientific Inc.
NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific Inc. (OTCQB: BRSF) (the “Company”), a neurology-focused medical device and software company, today announces that...